TITLE

Comparison of Microbiomes from Different Niches of Upper and Lower Airways in Children and Adolescents with Cystic Fibrosis

AUTHOR(S)
Boutin, Sébastien; Graeber, Simon Y.; Weitnauer, Michael; Panitz, Jessica; Stahl, Mirjam; Clausznitzer, Diana; Kaderali, Lars; Einarsson, Gisli; Tunney, Michael M.; Elborn, J. Stuart; Mall, Marcus A.; Dalpke, Alexander H.
PUB. DATE
January 2015
SOURCE
PLoS ONE;Jan2015, Vol. 10 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Changes in the airway microbiome may be important in the pathophysiology of chronic lung disease in patients with cystic fibrosis. However, little is known about the microbiome in early cystic fibrosis lung disease and the relationship between the microbiomes from different niches in the upper and lower airways. Therefore, in this cross-sectional study, we examined the relationship between the microbiome in the upper (nose and throat) and lower (sputum) airways from children with cystic fibrosis using next generation sequencing. Our results demonstrate a significant difference in both α and β-diversity between the nose and the two other sampling sites. The nasal microbiome was characterized by a polymicrobial community while the throat and sputum communities were less diverse and dominated by a few operational taxonomic units. Moreover, sputum and throat microbiomes were closely related especially in patients with clinically stable lung disease. There was a high inter-individual variability in sputum samples primarily due to a decrease in evenness linked to increased abundance of potential respiratory pathogens such as Pseudomonas aeruginosa. Patients with chronic Pseudomonas aeruginosa infection exhibited a less diverse sputum microbiome. A high concordance was found between pediatric and adult sputum microbiomes except that Burkholderia was only observed in the adult cohort. These results indicate that an adult-like lower airways microbiome is established early in life and that throat swabs may be a good surrogate in clinically stable children with cystic fibrosis without chronic Pseudomonas aeruginosa infection in whom sputum sampling is often not feasible.
ACCESSION #
100763888

 

Related Articles

  • Adults with cystic fibrosis need specialist care. Bryan, Jenny // BMJ: British Medical Journal (International Edition);06/27/98, Vol. 316 Issue 7149, p1929 

    Reports that delegates who attended the European cystic fibrosis conference held in Berlin, Germany, were told that adults with cystis fibrosis in parts of Europe and North America are missing out on specialist treatment. Increase in the number of patients with cystic fibrosis in countries;...

  • Erythromycin to prevent exacerbations of bronchiectasis. McNeill, Shea // Thorax;Feb2014, Vol. 69 Issue 2, p186 

    The article focuses on a study that discusses use of low-dose erythromycin to prevent pulmonary exacerbations in patients with non-cystic fibrosis (CF) brocnchiectasis. Topics discussed include prophylactic azithromycin used for elimination of exacerbation, randomized, double-blind,...

  • High-resolution computed tomography scores in cystic fibrosis patients colonized with Pseudomonas aeruginosa or Staphylococcus aureus. Folescu, Tania Wrobel; de Andrade Marques, Elizabeth; Boechat, Márcia Cristina Bastos; Daltro, Pedro; Higa, Laurinda Yoko Shinzato; Cohen, Renata Wrobel Folescu // Jornal Brasileiro de Pneumologia;jan2012, Vol. 38 Issue 1, p41 

    Objective: To compare HRCT findings in cystic fibrosis (CF) patients chronically colonized with Pseudomonas aeruginosa or Staphylococcus aureus using the modified Bhalla CT scoring system, as well as to evaluate intraobserver and interobserver reliability of the method. Methods: This was a...

  • Cystic fibrosis. Mayell, Sarah // Pulse;10/17/2012, Vol. 72 Issue 34, p30 

    The article presents a case study of an 11-year-old girl who is suffering from the cystic fibrosis since childhood. She was diagnosed with asthma and also received several courses of antibiotics in primary care but without any permanent response to the treatment. It offers information related to...

  • New drug for cystic fibrosis shows promise.  // Modern Medicine;Feb95, Vol. 63 Issue 2, p56 

    Presents an abstract of the article `Effect of Aerosolized Recombitant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis by H.J. Fuchs, D.S. Borowitz, et al from the periodical `The New England Journal of Medicine,' dated September 8,...

  • Cystic fibrosis therapy, detection improving.  // Newsweek;5/12/1986, Vol. 107 Issue 19, p69 

    Cystic fibrosis is one of the cruelest and most common genetically transmitted illnesses in the US, with more than 30,000 sufferers at any given time. Now, however, improvements in treatments are extending the lives of cystic fibrosis patients, and recent developments in biotechnology are...

  • Liberated lungs.  // New Scientist;8/21/93, Vol. 139 Issue 1887, p11 

    Reports on the recommendation for the approval of the pulmozyme drug by the Pulmonary-Allergy Drugs Advisory Committee to the Food and Drug Administration. Treatment for cystic fibrosis; Improvement of lung function; Alleviation of lung symptoms; Side effects.

  • Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis. Ramsey, Bonnie W.; Dorkin, Henry L.; Eisenberg, Jay D.; Gibson, Ronald L.; Harwood, Ivan R.; Kravitz, Richard M.; Schidlow, Daniel V.; Wilmott, Robert W.; Astley, Susan J.; McBurnie, Mary Ann; Wentz, Kim; Smith, Arnold L. // New England Journal of Medicine;6/17/93, Vol. 328 Issue 24, p1740 

    Background: Direct aerosol delivery of aminoglycosides such as tobramycin to the lower airways of patients with cystic fibrosis may control infection with Pseudomonas aeruginosa and improve pulmonary function, with low systemic toxicity. We conducted a randomized crossover study to evaluate the...

  • Closing in on cystic-fibrosis. Cowley, Geoffrey // Newsweek;5/3/1993, Vol. 121 Issue 18, p56 

    Reports that on April 17, a 23-year-old man with advanced cystic fibrosis became the first patient to receive a treatment aimed at correcting cystic-fibrosis, the fatal respiratory disorder, at its source. In an audacious experiment, doctors at the National Heart, Lung and Blood Institute...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics